Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
- Conditions
- Liver CancerLiver InjuryMalignancyIschemic Reperfusion InjuryCancer Recurrence
- Interventions
- Procedure: selective hepatic vascular exclusionProcedure: semielective hepatic vascular exclusion
- Registration Number
- NCT04257240
- Lead Sponsor
- Aretaieion University Hospital
- Brief Summary
Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.
- Detailed Description
One hundred and eighteen patients were subjected to liver resection under total inflow and outflow vascular clamping and were assigned as study group. These individuals were retrospectively matched to 112 counterparts, who underwent liver surgery applying inflow and outflow vascular clamping only of the segment harboring the tumor, sparing the liver remnant from any I/R injury (control group). The two cohorts were compared regarding recurrence-free survival and overall survival.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 230
- Adult patients
- American Society of Anesthesiologists (ASA) distribution I to III
- Patients scheduled for major liver resection (≥3 segments)
- patients with extrahepatic disease
- patients with metastatic liver tumors
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description study group selective hepatic vascular exclusion patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver control group semielective hepatic vascular exclusion patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
- Primary Outcome Measures
Name Time Method time to malignant recurrence from time of operation until time of malignant recurrence, assessed up to 15 years recurrence-free survival
time to death from time of operation until time of death, assessed up to 20 years overall survival
- Secondary Outcome Measures
Name Time Method aspartate aminotrasferase (AST) levels second postoperative day aspartate aminotransferase levels